Search

Your search keyword '"Perets, Tsachi Tsadok"' showing total 128 results
Start Over Author "Perets, Tsachi Tsadok"
128 results on '"Perets, Tsachi Tsadok"'

1. Author Correction: Repeated out-of-Africa expansions of Helicobacter pylori driven by replacement of deleterious mutations

Author

Thorpe, Harry A., Tourrette, Elise, Yahara, Koji, Vale, Filipa F., Liu, Siqi, Oleastro, Mónica, Alarcon, Teresa, Perets, Tsachi-Tsadok, Latifi-Navid, Saeid, Yamaoka, Yoshio, Martinez-Gonzalez, Beatriz, Karayiannis, Ioannis, Karamitros, Timokratis, Sgouras, Dionyssios N., Elamin, Wael, Pascoe, Ben, Sheppard, Samuel K., Ronkainen, Jukka, Aro, Pertti, Engstrand, Lars, Agreus, Lars, Suerbaum, Sebastian, Thorell, Kaisa, and Falush, Daniel

Published
2023
Full Text
View/download PDF

2. Repeated out-of-Africa expansions of Helicobacter pylori driven by replacement of deleterious mutations

Author

Thorpe, Harry A., Tourrette, Elise, Yahara, Koji, Vale, Filipa F., Liu, Siqi, Oleastro, Mónica, Alarcon, Teresa, Perets, Tsachi-Tsadok, Latifi-Navid, Saeid, Yamaoka, Yoshio, Martinez-Gonzalez, Beatriz, Karayiannis, Ioannis, Karamitros, Timokratis, Sgouras, Dionyssios N., Elamin, Wael, Pascoe, Ben, Sheppard, Samuel K., Ronkainen, Jukka, Aro, Pertti, Engstrand, Lars, Agreus, Lars, Suerbaum, Sebastian, Thorell, Kaisa, and Falush, Daniel

Published
2022
Full Text
View/download PDF

3. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

Author

Edelman-Klapper, Hadar, Zittan, Eran, Bar-Gil Shitrit, Ariella, Rabinowitz, Keren Masha, Goren, Idan, Avni-Biron, Irit, Ollech, Jacob E., Lichtenstein, Lev, Banai-Eran, Hagar, Yanai, Henit, Snir, Yifat, Pauker, Maor H., Friedenberg, Adi, Levy-Barda, Adva, Segal, Arie, Broitman, Yelena, Maoz, Eran, Ovadia, Baruch, Golan, Maya Aharoni, Shachar, Eyal, Ben-Horin, Shomron, Perets, Tsachi-Tsadok, Ben Zvi, Haim, Eliakim, Rami, Barkan, Revital, Goren, Sophy, Navon, Michal, Krugliak, Noy, Werbner, Michal, Alter, Joel, Dessau, Moshe, Gal-Tanamy, Meital, Freund, Natalia T., Cohen, Dani, and Dotan, Iris

Published
2022
Full Text
View/download PDF

4. Comparison of Four Tests for the Diagnosis of Helicobacter pylori Infection.

Author

Charach, Lior, Perets, Tsachi Tsadok, Gingold-Belfer, Rachel, Huta, Yair, Ashorov, Olga, Levi, Zohar, Dickman, Ram, and Boltin, Doron

Subjects
HELICOBACTER disease diagnosis, FECES, BACTERIAL antigens, RESEARCH evaluation, LOGISTIC regression analysis, CHEMILUMINESCENCE assay, HOST-bacteria relationships, MULTIVARIATE analysis, DESCRIPTIVE statistics, CLINICAL pathology, UREASE, INDIGESTION, LONGITUDINAL method, ATROPHY, METAPLASIA, ODDS ratio, GASTROSCOPY, STATISTICS, IMMUNOASSAY, STAINS & staining (Microscopy), INFLAMMATION, DATA analysis software, BREATH tests, HISTOLOGY, SENSITIVITY & specificity (Statistics), GASTROESOPHAGEAL reflux
Abstract

Background: Due to lower operational costs, health maintenance organizations (HMOs) may prioritize Helicobacter pylori stool antigen testing (HpStAg) for the non-invasive diagnosis of H. pylori infection over 13C-urea breath tests (13C-UBTs). The aim of our study was to compare the accuracy of the diagnostic tests for H. pylori. Methods: We performed histology, rapid urease test (RUT), 13C-UBT and HpStAg on consecutive patients referred for gastroscopy. Monoclonal stool antigen test was performed using the LIAISON Meridian chemiluminescent immunoassay. Histology was examined with hematoxylin and eosin, and additional stains were performed at the pathologist's discretion. For the assessment of 13C-UBT, we compared concordant histology and RUT. HpStAg was compared to the concordant results of two of the three remaining tests. Results: 103 patients were included (36 males (35.0%), age 50.1 ± 18.4 years). The indication for gastroscopy was dyspepsia in 63 (61.2%). Agreement between RUT and histology was 95.9%. For 13C-UBT and HpStAg, respectively, H. pylori positivity was 30% (30/100) and 27.16% (22/81); sensitivity was 97% and 70%; specificity was 100% and 94.4%; accuracy was 98% and 86%; positive predictive value (PPV) was 100% and 86.4%; negative predictive value (NPV) was 93% and 86%. No demographic, clinical, or endoscopic predictors of HpStAg accuracy were identified using logistic regression. Conclusions: 13C-UBT performs better than HpStAg at our institution. When interpreting results, clinicians should consider test limitations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

Author

Edelman-Klapper, Hadar, primary, Rabinowitz, Keren Masha, additional, Zittan, Eran, additional, Bar-Gil Shitrit, Ariella, additional, Goren, Idan, additional, Avni-Biron, Irit, additional, Ollech, Jacob E., additional, Lichtenstein, Lev, additional, Banai-Eran, Hagar, additional, Yanai, Henit, additional, Snir, Yifat, additional, Pauker, Maor H., additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Broitman, Yelena, additional, Ben Zvi, Haim, additional, Perets, Tsachi-Tsadok, additional, Eliakim, Rami, additional, Barkan, Revital, additional, Goren, Sophy, additional, Cohen, Dani, additional, and Dotan, Iris, additional

Published
2023
Full Text
View/download PDF

7. Gluten Immunogenic Peptides are not correlated with reported adherence to gluten-free diet in children with celiac disease

Author

Guz-Mark, Anat, primary, Perets, Tsachi Tsadok, additional, Biran, Neta, additional, Jack, Yifat, additional, Zevit, Noam, additional, Silbermintz, Ari, additional, Matar, Manar, additional, Nachmias-Friedler, Vered, additional, Waisbourd-Zinman, Orith, additional, Bar-Lev, Michal Rozenfeld, additional, Huta, Yair, additional, Ashorov, Olga, additional, Gingold-Belfer, Rachel, additional, and Shamir, Raanan, additional

Published
2023
Full Text
View/download PDF

10. Mo1586: A MICROBIOTA TARGETED, MEDITERRANEAN DIET-BASED NUTRITIONAL EDUCATION PROGRAM POSITIVELY MODIFIES THE INTESTINAL ECOSYSTEM OF HEALTHY INDIVIDUALS

Author

Godny, Lihi, primary, Reshef, Leah, additional, Fischler, Tali Sharar, additional, Elial-Fatal, Sarine, additional, Pfeffer-Gik, Tamar, additional, Raykhel, Barbara, additional, Rabinowitz, Keren M., additional, Levy-Barda, Adva, additional, Perets, Tsachi-Tsadok, additional, Barken, Revital, additional, Goren, Idan, additional, Ollech, Jacob, additional, Yanai, Henit A., additional, Gophna, Uri, additional, and Dotan, Iris, additional

Published
2022
Full Text
View/download PDF

11. Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES

Author

Rabinowitz, Keren M., primary, Navon, Michal, additional, Edelman-Klapper, Hadar, additional, Zittan, Eran, additional, Shitrit, Ariella Bar-Gil, additional, Goren, Idan, additional, Avni-Biron, Irit, additional, Ollech, Jacob, additional, Lichtenstein, Lev, additional, Banai, Hagar, additional, Yanai, Henit A., additional, Snir, Yifat, additional, H.Pauker, Maor, additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Segal, Arie, additional, Broitman, Yelena, additional, Maoz, Eran, additional, Ovadia, Baruch, additional, Golan, Maya Aharoni, additional, Shachar, Eyal, additional, Ben-Horin, Shomron, additional, Perets, Tsachi-Tsadok, additional, Zvi, Haim Ben, additional, Eliakim, Rami, additional, Barkan, Revital, additional, Goren, Sophy, additional, Krugliak, Noy, additional, Werbner, Michal, additional, Alter, Joel, additional, Dessau, Moshe, additional, Tanamy, Meital Gal, additional, Cohen, Daniel, additional, Freund, Natalia T., additional, and Dotan, Iris, additional

Published
2022
Full Text
View/download PDF

12. sj-docx-1-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Author

Yanai, Henit, Ungar, Bella, Kopylov, Uri, Fischler, Tali Sharar, Biron, Irit Avni, Ollech, Jacob E., Goren, Idan, Matar, Manar, Perets, Tsachi Tsadok, Shamir, Raanan, Dotan, Iris, Amir, Shira, and Assa, Amit

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tag-10.1177_17562848211068659 for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases by Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir and Amit Assa in Therapeutic Advances in Gastroenterology

Published
2022
Full Text
View/download PDF

13. sj-docx-2-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Author

Yanai, Henit, Ungar, Bella, Kopylov, Uri, Fischler, Tali Sharar, Biron, Irit Avni, Ollech, Jacob E., Goren, Idan, Matar, Manar, Perets, Tsachi Tsadok, Shamir, Raanan, Dotan, Iris, Amir, Shira, and Assa, Amit

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tag-10.1177_17562848211068659 for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases by Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir and Amit Assa in Therapeutic Advances in Gastroenterology

Published
2022
Full Text
View/download PDF

14. Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

Author

Yanai, Henit, primary, Ungar, Bella, additional, Kopylov, Uri, additional, Fischler, Tali Sharar, additional, Biron, Irit Avni, additional, Ollech, Jacob E., additional, Goren, Idan, additional, Matar, Manar, additional, Perets, Tsachi Tsadok, additional, Shamir, Raanan, additional, Dotan, Iris, additional, Amir, Shira, additional, and Assa, Amit, additional

Published
2022
Full Text
View/download PDF

17. Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

Author

Edelman-Klapper, Hadar, primary, Zittan, Eran, additional, Shitrit, Ariella Bar-Gil, additional, Rabinowitz, Keren Masha, additional, Goren, Idan, additional, Avni-Biron, Irit, additional, Ollech, Jacob E., additional, Lichtenstein, Lev, additional, Banai-Eran, Hagar, additional, Yanai, Henit, additional, Snir, Yifat, additional, Pauker, Maor H., additional, Friedenberg, Adi, additional, Levy-Barda, Adva, additional, Segal, Arie, additional, Broitman, Yelena, additional, Maoz, Eran, additional, Ovadia, Baruch, additional, Golan, Maya Aharoni, additional, Shachar, Eyal, additional, Ben-Horin, Shomron, additional, Perets, Tsachi-Tsadok, additional, Eliakim, Rami, additional, Goren, Sophy, additional, Navon, Michal, additional, Krugliak, Noy, additional, Werbner, Michal, additional, Alter, Joel, additional, Dessau, Moshe, additional, Gal-Tanamy, Meital, additional, Freund, Natalia T., additional, Cohen, Dani, additional, and Dotan, Iris, additional

Published
2021
Full Text
View/download PDF

19. A Novel Fecal Elastase Assay for the Detection of Pancreatic Exocrine Insufficiency.

Author

Huta, Yair, Ashorov, Olga, Hamouda, Dalal, Boltin, Doron, Dickman, Ram, and Perets, Tsachi Tsadok

Subjects
EXOCRINE pancreatic insufficiency, ELASTASES, CALPROTECTIN, PEARSON correlation (Statistics), REFERENCE values
Abstract

Background: Fecal pancreatic elastase 1 (FPE1) is an established screening test for pancreatic exocrine insufficiency (PEI), a condition that is underdiagnosed and if not treated may cause significant morbidity. The aim of this study was to compare a new FPE1 machine based CLIA kit to an ELISA assay which is considered the de facto gold standard in our laboratory for FPE1 measurement. Methods: Levels of FPE1 from the 227 stool samples were analyzed by the ScheBo ELISA kit and the CLIA Liaison XL system simultaneously with the same cutoff values for both assays. Performance of the Liaison XL system was assessed by calculating sensitivity, specificity, and accuracy. Results: The comparison between the Liaison XL system performance and the ScheBo ELISA kit as reference revealed a sensitivity, specificity, and accuracy of 86.8%, 94.3%, and 92.1%, respectively, using a cutoff of 100 µg FPE1/g stool. When the cutoff is 200 µg FPE1/g stool the sensitivity, specificity, and accuracy were 86.6%, 97.1%, and 90.7%, respectively. Furthermore, linear correlation of FPE1 levels between the two assays were found to be significant by Pearson's correlation coefficient test (R = 0.85, p-values < 0.0001). Conclusions: The Liaison XL system showed good laboratory performance with our pre-determined cutoff values when compared to our previous assay. An important advantage of this system is its semi-automated mechanism that enables large scale analysis of FPE1. In addition to that, the Liaison XL system is ideal for both qualitative and quantitative analysis of FPE1 allowing for its application to the clinical setting. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Effect of the transcutaneous electrical stimulation system on esophageal-acid exposure in patients non-responsive to once-daily proton-pump inhibitor: proof-of-concept study

Author

Dickman, Ram, primary, Levy, Sigal, additional, Perets, Tsachi Tsadok, additional, Hazani-Pauker, Maor, additional, Boltin, Doron, additional, Schmilovitz-Weiss, Hemda, additional, Nidal, Issa, additional, Siterman, Matan, additional, Carter, Dan, additional, Fass, Ronnie, additional, and Gingold-Belfer, Rachel, additional

Published
2021
Full Text
View/download PDF

23. Su1619 LOWER YIELD OF LIVER BIOPSY IN THE INVESTIGATION OF HEPATIC LESIONS

Author

Schmilovitz-Weiss, Hemda, primary, Shinhar, Nadav, additional, Weiss, Avraham, additional, Boltin, Doron, additional, Siterman, Matan, additional, Atar, Eli, additional, Issa, Nidal, additional, Sapoznikov, Boris, additional, Perets, Tsachi Tsadok, additional, Dickman, Ram, additional, Dotan, Iris, additional, and Gingold-Belfer, Rachel, additional

Published
2020
Full Text
View/download PDF

28. Clinical Accuracy of a New Rapid Assay for Fecal Calprotectin Measurement.

Author

Ashorov, Olga, Hamouda, Dalal, Dickman, Ram, and Perets, Tsachi Tsadok

Abstract

Background: Fecal calprotectin is an excellent biomarker for distinguishing inflammatory bowel disease from irritable bowel syndrome and for evaluation of disease activity in Crohn's disease and ulcerative colitis. The aim of this work was to evaluate the analytical performance of a new flow immune chromatography assay by comparing it to our standardized laboratory gold standard system. Methods: A total of 100 stool samples sent for routine calprotectin level measurements were analyzed by the Liaison XL system and the QuantOn Cal assay simultaneously using the same cutoff values for both assays. Performance of the QuantOn Cal assay was assessed by calculating sensitivity, specificity, and accuracy. Results: Compared with the gold standard, the sensitivity, specificity, and accuracy of the QuantOn Cal assay were 98.7%, 76.2%, and 94.0%, respectively. Furthermore, linear correlation of calprotectin levels between the two assays were found to be significant by Pearson's correlation coefficient test (r = 0.82, p-values < 0.0001). Conclusions: The QuantOn Cal assay demonstrated good performance, both qualitative and quantitative when compared to the Liaison XL system. This novel and rapid assay is well suited for measuring fecal calprotectin as a point of care or home-based assay when laboratory services are limited or not available. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

32. Su1218 - Disparities in Helicobacter Pylori Prevalencve Rate According to Socioeconomic Status, Country of Birth and Trends over Time in Adults Performing 13 C-Urea Breath Test at the Largest Israeli Health Maintenance Organization

Author

Leibovitzh, Haim, primary, Comaneshter, Doron, additional, Perets, Tsachi-Tsadok, additional, Boltin, Doron, additional, Gingold-Belfer, Rachel, additional, Arbiv, Orly Sneh, additional, Leibovici-Weissman, Yaara, additional, Cohen, Arnon, additional, Niv, Yaron, additional, Dotan, Iris, additional, Muhsen, Khitam, additional, and Levi, Zohar, additional

Published
2018
Full Text
View/download PDF

37. Su1218 - Disparities in Helicobacter Pylori Prevalencve Rate According to Socioeconomic Status, Country of Birth and Trends over Time in Adults Performing 13C-Urea Breath Test at the Largest Israeli Health Maintenance Organization

Author

Leibovitzh, Haim, Comaneshter, Doron, Perets, Tsachi-Tsadok, Boltin, Doron, Gingold-Belfer, Rachel, Arbiv, Orly Sneh, Leibovici-Weissman, Yaara, Cohen, Arnon, Niv, Yaron, Dotan, Iris, Muhsen, Khitam, and Levi, Zohar

Published
2018
Full Text
View/download PDF

38. Correlation between Quantitative 13C-Urea Breath Test and Helicobacter pylori Treatment Success in a Population-Based Cohort.

Author

Boltin, Doron, Levi, Zohar, Perets, Tsachi Tsadok, Schmilovitz-Weiss, Hemda, Gingold-Belfer, Rachel, Dickman, Ram, and Dotan, Iris

Subjects
BREATH tests, HELICOBACTER pylori infections, ENDOSCOPY, PATIENTS, COHORT analysis
Abstract

Background. There are continual efforts to identify factors which influence the success of first-line therapy for Helicobacter pylori (H. pylori) infection. The 13C-urea breath test result (C13-UBT) utilizes H. pylori urease activity and is a highly accurate diagnostic assay. We aimed to determine whether the magnitude of C13-UBT result is related to treatment success. Methods. Adult patients who underwent a first-time 13C-urea breath test between January 2010 and January 2016 were included. In order to isolate a naïve test-and-treat population who were unlikely to have undergone an initial endoscopy-based H. pylori test, we excluded patients > 45 years and those with a previous C13-UBT. Data were extracted from the Clalit Health Services laboratory database. Results. A total of 94,590 subjects (36.1% male, age 28.5 ± 6.0 years) who underwent a first-time C13-UBT during the study period were included. C13-UBT was positive in 48,509 (51.3%) subjects. A confirmatory posttreatment C13-UBT was performed in 18,375 (37.8%), and eradication was successful in 12,018 (65.4%). The mean C13-UBT recording was 20.6 ± 16.2 DOB in subjects with successful eradication and 19.5 ± 13.1 DOB in subjects with treatment failure (OR, 1.01; 95% CI 1.00-1.01, p<0.01). Among patients in the upper quintile of C13-UBT measurement, eradication was achieved in 67.6%, compared to 62.6% in the lower quintile (OR, 1.22; 95% CI 1.11-1.35, p<0.01). Subjects in the top 1 percentile (C13-UBT ≥ 70 DOB) achieved eradication in 75.0%, compared to 65.3% among subjects with C13-UBT < 70 DOB (OR, 1.59; 95% CI 1.05-2.41, p<0.01). Conclusions. The superiority in H. pylori eradication observed in subjects with a higher C13-UBT DOB is small but significant. Further studies should examine the physiological and microbiological basis for this finding. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. Circulating Bone Marrow-Derived CD45-/CD34+/CD133+/VEGF+ Endothelial Progenitor Cells in Adults with Crohn's Disease.

Author

Boltin, Doron, Kamenetsky, Zvi, Perets, Tsachi, Snir, Yifat, Sapoznikov, Boris, Schmilovitz-Weiss, Hemda, Ablin, Jacob, Dickman, Ram, Niv, Yaron, Perets, Tsachi Tsadok, and Ablin, Jacob Nadav

Subjects
BONE marrow, ENDOTHELIAL cells, PROGENITOR cells, CROHN'S disease, NEOVASCULARIZATION, VASCULAR endothelial growth factors, ANTIGEN analysis, BIOTHERAPY, INFLAMMATORY bowel disease treatment, ANTIGENS, CLASSIFICATION, PATIENTS, STATISTICS, MONONUCLEAR leukocytes
Abstract

Background: Circulating endothelial progenitor cells (EPCs) are bone marrow-derived stem cells able to migrate to sites of damaged endothelium and differentiate into endothelial cells. Altered EPC level and function have been described in various inflammatory diseases and have been shown to augment vasculogenesis in murine models. Previous studies of EPC in the context of Crohn's disease (CD) have yielded conflicting results.Aim: To determine whether the circulating levels of EPCs are changed in the context of CD.Methods: CD patients and healthy controls were recruited. Disease activity was assessed by CDAI. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using anti-CD34, anti-VEGF receptor-2, anti-CD133, and anti-CD45 markers.Results: Eighty-three subjects, including 32 CD patients and 51 controls were recruited, including 19 (59.4 %) and 23 (45 %) males (p = 0.26), aged 34.8 ± 14.9 and 43.3 ± 18.5 years (p = 0.64), in cases and controls, respectively. Mean CDAI was 147 ± 97, disease duration was 12.7 ± 11.1 years, and 28 (87.5 %) were receiving biologics for a mean duration of 21.7 ± 16.8 months. The mean level of peripheral EPCs in CD patients was 0.050 ± 0.086 percent and 0.007 ± 0.013 % in controls (p < 0.01). There was no significant correlation between EPC levels and age (r = -0.13, p = 0.47), CDAI (r = -0.26, p = 0.15), disease duration (r = -0.04, p = 0.84), or duration of treatment with biologics (r = 0.004, p = 0.99).Conclusion: EPCs are elevated in patients with CD. Further studies are needed to examine the function of EPCs and their possible role as a marker of disease severity or therapeutic response. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results